REG - Iconic Labs PLC - Results of Creditors and General Meetings

Iconic LabsAnnouncement

22/09/2022 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220922:nRSV3711Aa&default-theme=true

RNS Number : 3711A  Iconic Labs PLC  22 September 2022

Iconic Labs PLC

22 September 2022

 

 

Iconic Labs Plc - In Administration ("Iconic Labs" or the "Company")

Notice of Results of Creditors Meeting and General Meeting of Shareholders

 

Iconic Labs Plc (LSE:ICON hereby advises that it held a general meeting ("GM")
earlier today.

 

The CVA Proposal was approved by the requisite majorities of the creditors at
a meeting of the creditors held today at 11am.

 

At a meeting of the shareholders of the Company, held today at 2.00pm, all
resolutions were duly passed on a poll vote.

 

Details of the proxy voting are shown in the table below.

 

                                                                                 Votes For            %       Votes Against          %      Votes Total          Votes Withheld
 Ordinary resolutions:
 (1)  Approval of the Company Voluntary Arrangement ("CVA").                        10,009,834,608    97.49        257,331,813              10,267,166,421

                                                                                                                                     2.51                        48,068,796

 (2)  To empower the directors to generally allot relevant equity securities        10,240,735,765                  26,430,656                 10,267,166,421
 in respect of the CVA

                                                                                                      99.74                          0.26                        48,068,796

 (3)  To empower the directors to generally allot relevant equity securities        10,240,225,765                  26,430,656                 10,266,656,421
 to promote the success of the Company

                                                                                                      99.74                          0.26                        48,578,796

 Special resolutions:
 (4)  Subject to the passing of Resolution 2, to disapply the pre-emptive           10,009,324,608                 257,331,813                 10,266,656,421
 rights in respect of the relevant equity securities to be allotted in respect

 of CVA Proposal.                                                                                     97.49                          2.51                        48,578,796

 (5)  Subject to the passing of Resolution 3, to disapply the pre-emptive           10,240,225,765                  26,430,656                 10,266,656,421
 rights in respect of the relevant equity securities to be allotted to promote

 the success of the Company.                                                                          99.74                          0.26                        48,578,796

 

The full text of each of the resolutions is set out in the Notice of AGM,
available on the Company's website (www.iconiclabs.co.uk).

 

Market Abuse Regulation (MAR) Disclosure - Certain information contained in
this announcement would have been deemed inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 until the release of this
announcement.

 

For further information, please visit the Company's website
www.iconiclabs.co.uk (http://www.iconiclabs.co.uk/) or contact the Company via
ir@iconiclabs.co.uk (mailto:ir@iconiclabs.co.uk) .

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMBLGDCRSDDGDD